Skip to Content

Join the 'Crohn's Disease' group to help and get support from people like you.

Crohn's Disease News

Related terms: Crohns

Inflammatory Bowel Disease May Raise Cancer Risk in Kids

Posted 21 Sep 2017 by Drugs.com

THURSDAY, Sept. 21, 2017 – Children with inflammatory bowel disease (IBD) face an increased risk of cancer, a new study claims. The risk persists into adulthood, and is especially elevated for gastrointestinal cancers, the researchers added. The "extent and duration of chronic inflammation might be the main driving mechanisms underlying the increased risk of cancer," the researchers suggested. The international team, led by Dr. Ola Olen, a pediatric gastroenterologist at Karolinska Institute in Stockholm, compared about 9,400 patients in Sweden who were diagnosed with IBD before age 18 to a control group of nearly 93,000 people without IBD. The risk of cancer up to an average age of 30 was 3.3 cases per 1,000 person years among those with IBD. That compared with 1.5 cases per 1,000 person years in the control group. So, the overall risk of cancer among people with IBD is still low, the ... Read more

Related support groups: Cancer, Crohn's Disease, Colitis, Ulcerative Colitis, Crohn's Disease - Maintenance, Colorectal Cancer, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lymphocytic Colitis, Pseudomembranous Colitis, Noninfectious Colitis, Enterocolitis, Allergic Colitis

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** active psoriatic arthritis active ankylosing spondylitis (an arthritis that affects the spine) moderate to severe active adult Crohn’s disease moderate to severe active ulcerative colitis moderate to severe plaque psoriasis “Cyltezo is the first biosimilar from Boehringer Ingelheim to be approved by the FDA and marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients,” said Ivan Blanarik, Senior Vice President and Head of The ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Juvenile Rheumatoid Arthritis, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Humira Pen, Adalimumab, Amjevita, Cyltezo

Country Kids Less Likely to Develop Bowel Disease Than Their City Cousins

Posted 31 Jul 2017 by Drugs.com

MONDAY, July 31, 2017 – People in rural areas may be less likely to develop inflammatory bowel disease (IBD) than those in cities, Canadian researchers report. "Our findings show that children, particularly those under the age of 10, experience a protective effect against IBD if they live in a rural household," said study author Dr. Eric Benchimol. "This effect is particularly strong in children who are raised in a rural household in the first five years of life," said Benchimol, a pediatric gastroenterologist at Children's Hospital of Eastern Ontario in Ottawa. These are important findings, Benchimol said in a hospital news release, noting their previous work shows the number of very young children diagnosed with IBD has jumped in the past 20 years. IBD – which includes Crohn's disease and ulcerative colitis – is a lifelong condition that causes inflammation in the digestive tract, ... Read more

Related support groups: Crohn's Disease, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Crohn's Disease - Acute, Ulcerative Proctitis

Scientists Spot Genes Behind Crohn's, Ulcerative Colitis

Posted 29 Jun 2017 by Drugs.com

THURSDAY, June 29, 2017 – Researchers say they've come closer to pinpointing genes linked with inflammatory bowel diseases such as Crohn's and ulcerative colitis. For the study, the investigators examined the genomes of nearly 68,000 people. Of the regions of the genome associated with inflammatory bowel disease (IBD), 18 could be traced to a single genetic variant with more than 95 percent certainty. "We have taken the biggest ever data set for IBD and applied careful statistics to narrow down to the individual genetic variants involved," said study co-author Dr. Jeffrey Barrett, from the Wellcome Trust Sanger Institute in the United Kingdom. "Now we have a clearer picture of which genes do and do not play a role in the disease. We are zooming in on the genetic culprits of IBD," he said in an institute news release. The findings could lead to improved effectiveness of current ... Read more

Related support groups: Prednisone, Methylprednisolone, Crohn's Disease, Prednisolone, Ulcerative Colitis, Hydrocortisone, Medrol, Cortisone, Dexamethasone, Triamcinolone, Crohn's Disease - Maintenance, Betamethasone, Inflammatory Bowel Disease, Budesonide, Ulcerative Colitis - Active, Crohn's Disease - Acute, Entocort, Decadron, Ulcerative Colitis - Maintenance, Solu-Medrol

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Psoriatic Arthritis, Remicade, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

New Meds Make Inroads Against Crohn's Disease

Posted 13 Apr 2017 by Drugs.com

THURSDAY, April 13, 2017 – Fewer Americans with Crohn's disease are ending up in the hospital than in the past, according to a new federal study. Crohn's is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. Hospitalization rates for Crohn's disease remained stable in the United States between 2003 and 2013. That's a change from a study done from 1998 to 2004 that saw more than 4 percent increases in Crohn's hospitalizations each year, researchers with the U.S. Centers for Disease Control and Prevention said. The stable hospital rates are likely due to the 1998 introduction of a new class of biologic drugs. Examples of these medications used to treat Crohn's disease include: adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) and ustekinumab (Stelara), according to the U.S. National Institute of Diabetes and Digestive and Kidney ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Stelara, Ulcerative Colitis - Active, Cimzia, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Adalimumab, Infliximab, Inflectra, Amjevita, Certolizumab, Ustekinumab

Family History of Colon Cancer Calls for Earlier Screening

Posted 21 Mar 2017 by Drugs.com

TUESDAY, March 21, 2017 – If you've got a family history of colon or rectal cancers, you probably need to start screening for these conditions before you turn 50, a cancer expert says. People with a close relative who has had colon or rectal cancer have a greater risk of being diagnosed with these cancers too, said Dr. Walter Koltun, chief of colon and rectal surgery at the Penn State Health Hershey Medical Center in a hospital news release. "A significant portion of the population does have those risk factors," Koltun said. "And their risk goes up significantly depending on who has been affected." If more than one close relative has had colon or rectal cancer, your risk of getting such a cancer is 12 times greater, he added. People who are diagnosed with colon or rectal cancers at a young age are more likely to have a genetic trait that could increase their risk for the disease. ... Read more

Related support groups: Cancer, Breast Cancer, Crohn's Disease, Colonoscopy, Prostate Cancer, Colorectal Cancer, Inflammatory Bowel Disease, History - Radiation Therapy

Common Virus May Be Linked to Heart Disease, Diabetes in Some Women

Posted 23 Feb 2017 by Drugs.com

THURSDAY, Feb. 23, 2017 – A common virus may make some women more susceptible to both heart disease and type 2 diabetes, a new study suggests. Scientists at the University of California, San Francisco found normal-weight women under age 50 who were infected with cytomegalovirus (CMV) were more likely to have metabolic syndrome than their peers. Metabolic syndrome is a collection of risk factors for heart disease and diabetes that includes excess belly fat, unhealthy cholesterol levels, high blood pressure and high blood sugar levels. CMV, a herpes virus, is believed to infect roughly half of the U.S. population over the age of 40. Typically there are no symptoms unless the person's immune system is weakened. Ironically, obese women infected with CMV were less likely to have metabolic syndrome than obese women not infected with the virus, the researchers found. However, obese women were ... Read more

Related support groups: Diabetes, Type 2, Heart Disease, High Cholesterol, Crohn's Disease, Insulin Resistance, Crohn's Disease - Maintenance, Pre-Diabetes, Inflammatory Bowel Disease, Crohn's Disease - Acute, Viral Infection, Cytomegalovirus (CMV) Infection, Ulcerative Proctitis, Ischemic Heart Disease, CMV Pneumonia, CMV Retinitis, CMV Gastroenteritis

Special Diet May Be Boon for Kids With Crohn's, Colitis

Posted 10 Jan 2017 by Drugs.com

MONDAY, Jan. 9, 2017 – Children with Crohn's disease and ulcerative colitis may be able to achieve relief without medications by eating a special diet, a small study suggests. The diet includes non-processed foods, such as fruits, vegetables, meats and nuts. Over 12 weeks, the diet appeared to ease all signs of these inflammatory bowel diseases in eight of the 10 affected children, researchers report. "The study shows that without other intervention, other changes, we can improve individuals' clinical as well as laboratory markers," said study author Dr. David Suskind. He's a professor of pediatrics and director of clinical gastroenterology at Seattle Children's Hospital. "I'm not surprised," Suskind added, "primarily because preliminary studies ... opened our eyes to the idea that diet had an impact." Inflammatory bowel disease (IBD) affects about 1.6 million Americans, according to ... Read more

Related support groups: Crohn's Disease, Colitis, Ulcerative Colitis, Dietary Supplementation, Crohn's Disease - Maintenance, Asacol, Creon, Inflammatory Bowel Disease, Sulfasalazine, Pentasa, Ulcerative Colitis - Active, Lialda, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Apriso, Lactaid, Mesalamine, Canasa, Zenpep, Pancrease

Drug Stelara May Ease Crohn's Disease

Posted 18 Nov 2016 by Drugs.com

THURSDAY, Nov. 17, 2016 – People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of the inflammatory agents interleukin-12 and interleukin-23. The drug had been approved for the treatment of psoriasis and is now approved for treating Crohn's disease as well. Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Crohn's usually affects the end of the small bowel and the beginning of the colon. But it may affect any part of the gastrointestinal tract, from the mouth to the anus, according to the Crohn's and Colitis Foundation of America (CCFA). Crohn's can cause diarrhea, rectal bleeding, an urgent need to move the bowels, stomach cramps, pain and constipation, the CCFA says. "Stelara is effective for ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Crohn's Disease - Maintenance, Stelara, Cimzia, Crohn's Disease - Acute, Ustekinumab

The Scoop About Healthy Poop

Posted 25 Oct 2016 by Drugs.com

TUESDAY, Oct. 25, 2016 – Your bowel movements can offer important clues about your health, a doctor says. If bowel movements feel comfortable, then it's likely all is well, said Dr. Gabriel Neal, a family medicine doctor and clinical assistant professor at Texas A&M College of Medicine. "Normal bowel movements are relatively soft but dense. They should be any shade of brown or green," Neal said in a college news release. Viruses and bacteria in the intestinal tract can cause stool discoloration, diarrhea or blood in the stool. The color of the blood can help your doctor pinpoint the location of the infection. "If an infection is in the lower intestines or colon, then the blood in your stool is going to be red. If you find black blood, then the blood has oxidized and is from higher up in your digestive tract, such as the stomach or upper intestines," Neal said. People with gallbladder ... Read more

Related support groups: Diarrhea, Constipation, Crohn's Disease, Constipation - Chronic, Gastrointestinal Disorders, Inflammatory Bowel Disease, Gallbladder Disease, Constipation - Acute, Diarrhea, Chronic, Diarrhea, Acute, Infectious Diarrhea

Study Identifies Genetic Subtypes of Crohn's Disease

Posted 14 Oct 2016 by Drugs.com

FRIDAY, Oct. 14, 2016 – Crohn's disease appears to have at least two distinct genetic subtypes, which could explain why the condition is so hard to treat, a new study suggests. "The one-treatment-fits-all approach doesn't seem to be working for Crohn's patients," said study co-senior author Dr. Shehzad Sheikh. He's an assistant professor in the departments of medicine and genetics at the University of North Carolina School of Medicine. "It's plausible that this is because only a subset of patients has the type of disease that responds to standard therapy, whereas, for the rest of the patients, we're really not hitting the right targets," Sheikh said in a university news release. Crohn's is a chronic inflammatory disorder of the intestinal tract. The most common symptoms are diarrhea, stomach cramps and weight loss. The course and severity of the disease vary widely from patient to ... Read more

Related support groups: Humira, Crohn's Disease, Crohn's Disease - Maintenance, Asacol, Inflammatory Bowel Disease, Stelara, Sulfasalazine, Pentasa, Lialda, Crohn's Disease - Acute, Apriso, Mesalamine, Canasa, Diagnosis and Investigation, Delzicol, Asacol HD, Azulfidine, Sulfazine, Rowasa, Azulfidine EN-tabs

FDA Approves Stelara (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease

Posted 27 Sep 2016 by Drugs.com

HORSHAM, Pa., Sept. 26, 2016 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers. Stelara is the first biologic therapy for Crohn's disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses. "Crohn's disease is a complex condition to treat, and not all therapies work for every patient," said William J. Sandborn, MD, Chief, Division of Gastroenterology, and Professor of Medicine, UC San Diego School of Medicine, and ... Read more

Related support groups: Crohn's Disease, Stelara, Ustekinumab

Amjevita Approved to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis and juvenile idiopathic arthritis, the FDA said in a news release. Biological drugs are generally derived from a living organism and can come from many sources, including humans, animals, microorganisms or yeast, the FDA said. A biosimilar drug is a biological product that's sanctioned after its maker proves it is "highly similar" to an already-approved biologic drug. The manufacturer of the biosimilar drug must prove that the product has "no clinically meaningful differences" in safety, purity ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Amjevita

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis. Amjevita is also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of age and older. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. “This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new fr ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Adalimumab, Amjevita

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Crohn's Disease - Maintenance, Crohn's Disease - Acute, Inflammatory Bowel Disease

Related Drug Support Groups

Topamax, Cipro, Humira, ciprofloxacin, topiramate, Remicade, Asacol, cholestyramine, Imuran, view more... hyoscyamine, sulfasalazine, Stelara, Pentasa, budesonide, Lialda, cyclosporine, Cimzia, tacrolimus, azathioprine, rifaximin, Entocort EC, Questran, Prevalite, Apriso, mycophenolate mofetil, Entyvio, mesalamine, Canasa, adalimumab, infliximab, Neoral, Levsin, Levsin SL, Asacol HD, balsalazide, Symax Duotab, HyoMax, Inflectra, Anaspaz, Hyosyne, Topamax Sprinkle, vedolizumab, Cholestyramine Light, Cyltezo, Sandimmune, Symax FasTab, Gengraf, Hyosol, Azasan, HyoMax SR, HyoMax SL, certolizumab, Amjevita, Renflexis, ustekinumab, Rowasa, Questran Light, HyoMax DT, Cipro XR, Locholest, Gastrosed, Locholest Light, Cipro IV, Colazal, Colidrops, Oscimin, Ed-Spaz, Topiragen, Mesasal Enteric Coated, HyoMax FT, Symax SR, FIV-ASA, Spasdel, Levsinex, NuLev, A-Spaz, Levbid, Cystospaz, Salofalk, Cystospaz-M, Levsinex SR, Symax SL, A-Spas S / L, Donnamar, IB-Stat, Hyospaz, Canasa Pac